Photoresponsive Nanovehicle for Two Independent Wavelength Light-Triggered Sequential Release of P-gp Shrna and Doxorubicin to Optimize and Enhance Synergistic Therapy of Multidrug-Resistant Cancer
Ming Wu,Xinyi Lin,Xionghong Tan,Jiong Li,Zuwu Wei,Da Zhang,Youshi Zheng,Ai-xian Zheng,Bixing Zhao,Yongyi Zeng,Xiaolong Liu,Jingfeng Liu
DOI: https://doi.org/10.1021/acsami.8b03823
IF: 9.5
2018-01-01
ACS Applied Materials & Interfaces
Abstract:Prerelease of RNA molecules than chemotherapeutic drugs with a sufficient interval is a vital prerequisite for RNA/drug co-delivery strategy to overcome multidrug resistance (MDR) of cancer cells, but how to precisely control their release at different time points is still a grand challenge up to now. This study aims to on-demand remotely manipulate RNA and drug release in real time through single delivery system to sequentially play their respective roles for optimizing and enhancing their synergistic antitumor effects. To this end, a photoresponsive mesoporous silica nanoparticle (PMSN) is fabricated as a co-delivery vehicle of P-glycoprotein (P-gp) short-hairpin RNA (shRNA) and photocaged prodrug of doxorubicin (DOX), by which the orthogonal and sequential release of shRNA and DOX can be achieved using an external light. In our design, the cationic poly[2-(N,N-dimethylaminoethyl)- methacrylate] is introduced onto the PMSN surface through a light-sensitive coumarin ester derivative linker to adsorb P-gp shRNA, whereas the photocleavable o-nitrobenzyl ester derivative-caged DOX is loaded into the inner pores of the PMSN. The PMSN is found to be effectively internalized by MDR cancer cells, and the release of the shRNA and DOX is demonstrated to be independently regulated by 405 and 365 nm light irradiations due to selectively cleaved coumarin and o-nitrobenzyl ester, resulting in enhanced drug retention, and finally bring out optimized and significantly improved chemotherapeutic effects both in vitro and in vivo for MDR cancer treatment, which might hold extensive application prospects in MDR cancer treatment in future.